To investigate efficacy and safety of clozapine treatment for schizophrenia focusing on plasma clozapine concentrations and cytokine levels.

To investigate clinical significance of plasma clozapine concentrations and cytokine levels. - Clinical significance of plasma clozapine concentrations and cytokine levels

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000048075

Enrollment

Registered

2022-06-17

Start date

2022-06-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psychiatric disorder

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects include patients who receive clozapine treatment for the first time from June 2022 at Kusatsu Hospital, Hiroshima, Japan.

Exclusion criteria

Exclusion criteria: If informed consent is not available.

Design outcomes

Primary

Measure	Time frame
Sequential changes regarding plasma clozapine concentrations and cytokine levels after administration of clozapine	—

Countries

Japan

Contacts

Public ContactMASARU NAKAMURA

Kosekai Cocoro Hospital Kusatsu Internal Medicine

smile1012nakamura@nifty.com0822771001

Outcome results